Patents by Inventor Michinori OIKAWA

Michinori OIKAWA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11826473
    Abstract: Provided is an orally disintegrating tablet film-coated with a composition for film coating containing hypromellose and hydroxypropyl cellulose but not containing a plasticizer.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: November 28, 2023
    Assignee: SAWAI PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Yamamoto, Ayane Natsume, Yuki Nishikawa, Michinori Oikawa, Hiroaki Kikuoka
  • Patent number: 11406600
    Abstract: An anhydrous dasatinib-containing preparation comprising an anhydrous dasatinib and a titanium oxide or colorant or antioxidant is provided. In one embodiment, the anhydrous dasatinib-containing preparation improves photostability upon storage. The weight ratio of the titanium oxide per the anhydrous dasatinib may be more than 0 and 2 or less, or the weight ratio of the colorant per the anhydrous dasatinib may be more than 0 and 1 or less, or the weight ratio of the antioxidant per the anhydrous dasatinib may be more than 0 and 0.5 or less.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: August 9, 2022
    Assignee: SAWAI PHARMACEUTICAL CO., LTD.
    Inventors: Michinori Oikawa, Hiroyuki Yamamoto, Hiroaki Kikuoka
  • Patent number: 10842760
    Abstract: A sustained-release preparation containing pseudoephedrine is provided comprising pseudoephedrine or a pharmaceutically acceptable salt thereof, and a hardened oil or stearic acid. The sustained-release preparation containing pseudoephedrine may contain a hardened oil or stearic acid in an amount of 100% by mass to 500% by mass with respect to the content of the pseudoephedrine or a pharmaceutically acceptable salt thereof. In addition, the sustained-release preparation containing pseudoephedrine may have a first part and a second part, the first part may contain the pseudoephedrine or a pharmaceutically acceptable salt thereof, and the first part or the second part may contain an optional active ingredient.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 24, 2020
    Assignee: SAWAI PHARMACEUTICAL CO., LTD.
    Inventors: Yuki Nishikawa, Hiroaki Kikuoka, Michinori Oikawa, Hiroyuki Yamamoto, Tomoya Nakagawa
  • Publication number: 20200281859
    Abstract: An anhydrous dasatinib-containing preparation comprising an anhydrous dasatinib and a titanium oxide or colorant or antioxidant is provided. In one embodiment, the anhydrous dasatinib-containing preparation improves photostability upon storage. The weight ratio of the titanium oxide per the anhydrous dasatinib may be more than 0 and 2 or less, or the weight ratio of the colorant per the anhydrous dasatinib may be more than 0 and 1 or less, or the weight ratio of the antioxidant per the anhydrous dasatinib may be more than 0 and 0.5 or less.
    Type: Application
    Filed: May 20, 2020
    Publication date: September 10, 2020
    Inventors: Michinori OIKAWA, Hiroyuki YAMAMOTO, Hiroaki KIKUOKA
  • Patent number: 10588856
    Abstract: Provided is an orally disintegrating tablet coated with film that allows the time elapsed before a film thereof dissolves to be shorter, has a good feel when the tablet is taken, and is capable of being easily mass-produced. The orally disintegrating tablet coated with film is coated with a film coating composition, the film coating composition comprises a water-soluble and ethanol-insoluble film coating base; and at least one plasticizer selected from the group consisting of propylene glycol and polyethylene glycol in a liquid or semisolid state at room temperature.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 17, 2020
    Assignee: SAWAI PHARMACEUTICAL CO., LTD.
    Inventors: Michinori Oikawa, Hiroyuki Yamamoto, Hiroaki Kikuoka
  • Publication number: 20190388363
    Abstract: A sustained-release preparation containing pseudoephedrine is provided comprising pseudoephedrine or a pharmaceutically acceptable salt thereof, and a hardened oil or stearic acid. The sustained-release preparation containing pseudoephedrine may contain a hardened oil or stearic acid in an amount of 100% by mass to 500% by mass with respect to the content of the pseudoephedrine or a pharmaceutically acceptable salt thereof. In addition, the sustained-release preparation containing pseudoephedrine may have a first part and a second part, the first part may contain the pseudoephedrine or a pharmaceutically acceptable salt thereof, and the first part or the second part may contain an optional active ingredient.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Inventors: Yuki NISHIKAWA, Hiroaki KIKUOKA, Michinori OIKAWA, Hiroyuki YAMAMOTO, Tomoya NAKAGAWA
  • Publication number: 20190231700
    Abstract: Provided is an orally disintegrating tablet film-coated with a composition for film coating containing hypromellose and hydroxypropyl cellulose but not containing a plasticizer.
    Type: Application
    Filed: January 10, 2019
    Publication date: August 1, 2019
    Inventors: Hiroyuki YAMAMOTO, Ayane NATSUME, Yuki NISHIKAWA, Michinori OIKAWA, Hiroaki KIKUOKA
  • Publication number: 20160346199
    Abstract: Provided is an orally disintegrating tablet coated with film that allows the time elapsed before a film thereof dissolves to be shorter, has a good feel when the tablet is taken, and is capable of being easily mass-produced. The orally disintegrating tablet coated with film is coated with a film coating composition, the film coating composition comprises a water-soluble and ethanol-insoluble film coating base; and at least one plasticizer selected from the group consisting of propylene glycol and polyethylene glycol in a liquid or semisolid state at room temperature.
    Type: Application
    Filed: August 10, 2016
    Publication date: December 1, 2016
    Inventors: Michinori OIKAWA, Hiroyuki YAMAMOTO, Hiroaki KIKUOKA